Screener
Celldex Therapeutics CLDX Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $47.45M+106% | $35.73M+109% | $28.87M+1.8% | $36.04M-1.0% | $23.04M-46.1% | ||
| $670.13M+10.3% | $415.73M-36.6% | $489.7M-29.7% | $547.19M-24.0% | $607.29M-20.0% | ||
| $230K+156% | $230K-78.4% | $2.02M+188% | $90K-89.4% | $90K-94.1% | ||
| $724.93M+11.8% | $459.22M-33.8% | $534.66M-28.4% | $604.34M-22.4% | $648.4M-20.1% | ||
| $9.76M+122% | $7.4M+60.7% | $5.33M+22.7% | $4.83M+14.2% | $4.39M+13.7% | ||
| $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | ||
| $782.35M+13.0% | $511.25M-30.9% | $582.98M-26.4% | $648.44M-21.2% | $692.41M-18.1% | ||
| $14.68M+608% | $10.36M+204% | $1.18M-63.9% | $4.27M+283% | $2.07M-45.5% | ||
| $61.33M+86.0% | $51.47M+60.8% | $50.99M+29.1% | $46.47M+44.8% | $32.96M+19.2% | ||
| $67.79M+83.2% | $55.03M+50.8% | $55.82M+23.1% | $50.08M+34.3% | $37M+15.9% | ||
| $79K+19.7% | $67K+1.5% | $67K+1.5% | $66K0.0% | $66K0.0% | ||
| -$1.97B-18.0% | -$1.89B-17.6% | -$1.81B-16.6% | -$1.73B-14.9% | -$1.67B-13.6% | ||
| $714.56M+9.0% | $456.23M-35.1% | $527.17M-29.4% | $598.36M-23.9% | $655.41M-19.4% | ||
| $782.35M+13.0% | $511.25M-30.9% | $582.98M-26.4% | $648.44M-21.2% | $692.41M-18.1% |
FAQ
- What are Celldex Therapeutics's total assets?
- Celldex Therapeutics (CLDX) holds $782.3M in total assets, up 13.0% year over year.
- How much debt does Celldex Therapeutics have?
- Celldex Therapeutics carries $4.9M in total debt against $714.6M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Celldex Therapeutics have?
- Celldex Therapeutics holds $47.5M in cash and equivalents.
- Can Celldex Therapeutics cover its short-term obligations?
- Its current ratio is 11.82 — current assets exceed current liabilities.
- Where does Celldex Therapeutics's balance sheet data come from?
- Every line is extracted from Celldex Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
